Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

TCT 2021 | ESH CML/MPNs 2021: what to expect?

Ruben Mesa • 17 Feb 2021
TCT 2021
Chronic Myeloid Leukemia Myelofibrosis Myeloproliferative Neoplasms Polycythemia Vera Rare Diseases

Ruben Mesa, MD, UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, discusses the upcoming 2nd How to Diagnose and Treat CML/MPN meeting, an international virtual European School of Hematology (ESH) meeting which will translate key updates in the treatment and management of chronic myeloid leukemia and myeloproliferative neoplasms. This interview took place during the Transplantation & Cellular Therapy (TCT) 2021 Meetings.

More from Ruben Mesa

Guidance for selecting between JAK inhibitors in the frontline and second-line setting for MF
1:26
Guidance for selecting between JAK inhibitors in the frontline and second-line setting for MF
Ruben Mesa • 6 Dec 2025
An overview of ongoing Phase III trials investigating novel treatment options for myelofibrosis
1:40
An overview of ongoing Phase III trials investigating novel treatment options for myelofibrosis
Ruben Mesa • 6 Dec 2025
The MPN Journal: a web-based platform developed by patients for patients
1:05
The MPN Journal: a web-based platform developed by patients for patients
Ruben Mesa • 6 Dec 2025
Impact of thrombocytopenia in JAK inhibitor–naive myelofibrosis treated with ruxolitinib
1:12
Impact of thrombocytopenia in JAK inhibitor–naive myelofibrosis treated with ruxolitinib
Ruben Mesa • 6 Dec 2025

Related Videos

Guidance for selecting between JAK inhibitors in the frontline and second-line setting for MF
1:26
Guidance for selecting between JAK inhibitors in the frontline and second-line setting for MF
Ruben Mesa • 6 Dec 2025
Results of the ASC2ESCALATE trial of asciminib in CML-CP with one prior TKI
2:34
Results of the ASC2ESCALATE trial of asciminib in CML-CP with one prior TKI
Ruben Mesa • 7 Dec 2025
Asciminib in patients with CML-CP who have not achieved DMR after ≥1 year of imatinib: ASC4MORE
2:15
Asciminib in patients with CML-CP who have not achieved DMR after ≥1 year of imatinib: ASC4MORE
Ruben Mesa • 7 Dec 2025
An overview of ongoing Phase III trials investigating novel treatment options for myelofibrosis
1:40
An overview of ongoing Phase III trials investigating novel treatment options for myelofibrosis
Ruben Mesa • 6 Dec 2025
The content of VJHemOnc is intended for healthcare professionals